PTPRC and neoplasm: These analyses revealed a slight delay in primary tumour growth when treated with CD63 peptide and a significant decrease with CD9 peptide (Figure 5b), with no significant effects in tumour angiogenesis (Figure 5c) but a significant reduction in tumour infiltration, of both neutrophils (assessed by myeloperoxidase staining) and of total leukocytes (with CD45 staining) (Figure 5d and data not shown).